TY - JOUR
T1 - Quantifying Flavin mononucleotide
T2 - an internationally validated methodological approach for enhanced decision making in organ transplantation
AU - Sun, Keyue
AU - Jiao, Chunbao
AU - Panconesi, Rebecca
AU - Satish, Sangeeta
AU - Karakaya, Omer F.
AU - De Goeij, Femke H.C.
AU - Diwan, Tobias
AU - Ali, Khaled
AU - Cadinu, Lorenzo A.
AU - Cazzaniga, Beatrice
AU - Liu, Qiang
AU - Miyazaki, Yuki
AU - Pita, Alejandro
AU - Khalil, Mazhar
AU - Kim, Jae Keun
AU - Hussein, Ahmed
AU - Müller, Philipp C.
AU - Aucejo, Federico
AU - Kwon, David H.C.
AU - Fernandes, Eduardo
AU - Esfeh, Jamak Modaresi
AU - Cywinski, Jacek
AU - Fujiki, Masato
AU - Sun, Lidong
AU - Pinna, Antonio
AU - Dutkowski, Philipp
AU - Wehrle, Chase J.
AU - Fairchild, Robert L.
AU - Meierhofer, David
AU - De Jonge, Jeroen
AU - Miller, Charles
AU - Hashimoto, Koji
AU - Schlegel, Andrea
N1 - Publisher Copyright: © 2025 The Authors
PY - 2025/6
Y1 - 2025/6
N2 - Background: Increasing donor risk, particularly in liver transplantation, where organs are often marginal, has made dynamic organ preservation techniques and viability assessment essential to safely improve organ quality and increase utilisation. However, existing viability parameters are based on routine clinical assessment in patients with acute liver failure, trauma, or liver resections. These parameters often do not correlate with clinically relevant post-transplant outcomes. Methods: This article presents a detailed protocol for the spectrophotometric quantification of Flavin mononucleotide (FMN), a marker of mitochondrial injury. FMN release from mitochondrial complex I was described many decades ago as the initial sign of ischaemia-reperfusion injury, i.e. when oxygen is reintroduced in ischaemic tissues during organ transplantation or machine perfusion. This study describes the detailed FMN quantification in donor plasma and various fluids obtained during machine perfusion, and discusses confounders, challenges, and the role of individual test components. Findings: FMN quantification was identified as an immediate organ assessment tool, demonstrating a strong correlation with graft survival and other relevant complications after human liver transplantation. Interpretation: The results highlight FMN quantification as a reliable and standardized method for assessing organ viability, offering significant potential for improving organ selection and better utilisation. This method could provide better a predictive value for transplant outcomes compared to existing parameters currently in use. Funding: This research received no external funding but was supported by the Catalyst grant No. CCG0280 at Cleveland Clinic Ohio, U.S. dedicated to A.S.
AB - Background: Increasing donor risk, particularly in liver transplantation, where organs are often marginal, has made dynamic organ preservation techniques and viability assessment essential to safely improve organ quality and increase utilisation. However, existing viability parameters are based on routine clinical assessment in patients with acute liver failure, trauma, or liver resections. These parameters often do not correlate with clinically relevant post-transplant outcomes. Methods: This article presents a detailed protocol for the spectrophotometric quantification of Flavin mononucleotide (FMN), a marker of mitochondrial injury. FMN release from mitochondrial complex I was described many decades ago as the initial sign of ischaemia-reperfusion injury, i.e. when oxygen is reintroduced in ischaemic tissues during organ transplantation or machine perfusion. This study describes the detailed FMN quantification in donor plasma and various fluids obtained during machine perfusion, and discusses confounders, challenges, and the role of individual test components. Findings: FMN quantification was identified as an immediate organ assessment tool, demonstrating a strong correlation with graft survival and other relevant complications after human liver transplantation. Interpretation: The results highlight FMN quantification as a reliable and standardized method for assessing organ viability, offering significant potential for improving organ selection and better utilisation. This method could provide better a predictive value for transplant outcomes compared to existing parameters currently in use. Funding: This research received no external funding but was supported by the Catalyst grant No. CCG0280 at Cleveland Clinic Ohio, U.S. dedicated to A.S.
UR - https://www.scopus.com/pages/publications/105006567479
U2 - 10.1016/j.ebiom.2025.105761
DO - 10.1016/j.ebiom.2025.105761
M3 - Article
C2 - 40435722
AN - SCOPUS:105006567479
SN - 2352-3964
VL - 116
JO - EBioMedicine
JF - EBioMedicine
M1 - 105761
ER -